Placebo News and Research

RSS

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Australian health care company Prima BioMed Ltd announced today that there has been an agreement for strategy and design of the Phase III clinical registration trial for the CVac™ immunotherapy therapeutic ovarian cancer vaccine.

19 Feb 2011

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Novavax, a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials.

19 Feb 2011

Boys get greater rush and more energy from caffeine than girls

Results of a double-blind, placebo-controlled, dose-response study of the response of youth to caffeine found that, in general, boys get a greater rush and more energy from caffeine than girls.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

Cytochroma today announced the initiation of a repeat-dose safety and efficacy study of CTAP101 Capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT) and stage 3 chronic kidney disease (CKD).

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management

A recent multicenter clinical trial of atorvastatin, a type of cholesterol-lowering drug, found that although the drug did not inhibit plasma HIV RNA levels, it did inhibit expression of cellular markers of immune activation and inflammation in patients with HIV infection.

17 Feb 2011

Flu vaccine update

This new vaccine which could become available in the United States in the next few years, is made by growing the influenza virus in cultures of animal cells rather than in the chicken eggs that have been used for more than five decades. This shortens the process by six months. Using animal cells, which are grown in enclosed steel tanks, also reduces the risk of bacterial contamination, which has led to shortages of seasonal vaccines in some years. The study was reported in The Lancet this Tuesday.

16 Feb 2011

Patients with chronic low-back pain can benefit from spinal manipulation

If you're suffering from chronic lower back pain, a new review of existing research finds that spinal manipulation − the kind of hands-on regimen that a chiropractor might perform on you − is as helpful as other common treatments like painkillers.

15 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Efficacy of zinc in common cold - Review of clinical trials

A new study has added to the existing literature that debates the role of zinc in combating the common cold. It suggests that the supplement might modestly reduce cold duration and severity or maybe even prevent it. The report was published as a Cochrane Review.

15 Feb 2011

Study confirms anti-inflammatory properties of Oligonol in humans

A recently published study in Nutrition Research and Practice has verified the anti-inflammatory effects in humans of Oligonol® lychee fruit polyphenol. The study examined Oligonol intake on cortisol and related cytokines in healthy young men. Both cortisol and cytokine concentrations are inflammatory markers known to increase when stress such as exercise is caused on the body.

15 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.

14 Feb 2011

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Napo Pharmaceuticals, Inc. is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd..

14 Feb 2011

SynthRx to become wholly-owned subsidiary of ADVENTRX

ADVENTRX Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to acquire SynthRx, Inc., a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188.

14 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

Placebo News and Research

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Boys get greater rush and more energy from caffeine than girls

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management

Flu vaccine update

Patients with chronic low-back pain can benefit from spinal manipulation

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Efficacy of zinc in common cold - Review of clinical trials

Study confirms anti-inflammatory properties of Oligonol in humans

State court jury rules in favor of Merck in FOSAMAX trial

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

SynthRx to become wholly-owned subsidiary of ADVENTRX

Phase III RISE study of Lucentis for DME meets primary endpoint

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News